The positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use for Novo Nordisk's Sogroya is a significant milestone for the company. This approval will likely lead to increased sales and revenue for Novo Nordisk, as it expands the market for Sogroya to children and adolescents with growth hormone deficiency. This news is expected to have a positive short-term impact on Novo Nordisk's stock price.